Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.4
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very weak growth
Data is available to registered users only
Data is available to registered users only
About
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Data is available to registered users only
Buy
Sell